Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
BETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s management team will participate in a fireside chat and one-on-one meetings at the Oppenheimer 36
Fireside Chat Details
Date: Wednesday, February 25, 2026
Time: 1:20 p.m. ET
Registered attendees can request one-on-one meetings with Gain management via their Oppenheimer banking representative.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.
Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Amid Lower Oil Prices
09:12 AM EDT, 10/06/2026 (MT Newswires) -- The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5% and the actively traded Invesco QQQ Trust (QQQ) was 0.6% higher in Tuesday's premarket activity amid lower oil prices and optimism around tech stocks. US stock futures were also higher, with S&P 500 Index futures up 0.5%, Dow Jones Industrial Average futures advancing 0.7%, and Nasdaq futures gaining 0.7% before the start of regular trading. The US international trade deficit widened to $105.57 billion in August from a $92.83 billion gap in July, compared with a $102.1 billion gap expected in a survey compiled by Bloomberg as of 7:35 am ET. In premarket activity, bitcoin was up by 0.7%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 1% higher, Ether ETF (EETH) advanced 1.6%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was flat. Power Play: Health Care The State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.3%, while the Vanguard Health Care Index Fund (VHT) and the iShares US Healthcare ETF (IYH) were inactive. The iShares Biotechnology ETF (IBB) was 0.7% higher. Option Care Health (OPCH) shares were up 21% pre-bell Tuesday after McKesson (MCK) and CD&R agreed to buy the company for roughly $5.80 billion. Winners and Losers: Technology The State Street Technology Select Sector SPDR ETF (XLK) gained 0.7%, the iShares US Technology ETF (IYW) was 0.5% higher, and the iShares Expanded Tech Sector ETF (IGM) was inactive. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was inactive, while the iShares Semiconductor ETF (SOXX) rose by 0.5%. Xanadu Quantum Technologies (XNDU) shares were up 7% in premarket activity after the company entered a multiyear deal with GlobalFoundries (GFS). GlobalFoundries was 1.4% higher. Financial The State Street Financial Select Sector SPDR ETF (XLF) advanced 0.3%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.9%, while its bearish counterpart, Direxion Daily Financial Be
Iran Tries to Oust Diplomat Who Met Trump Envoys: Will It Reverse Oil Price Slide?
EasyA Co-Founder Phil Kwok Drops Bombshell Statement for XRP Army
CENOVUS ENERGY INCORPORATION <CVE.TO>: RAYMOND JAMES RAISES TARGET PRICE TO C$53 FROM C$51
CENOVUS ENERGY INCORPORATION : RAYMOND JAMES RAISES TARGET PRICE TO C$53 FROM C$51
Crypto prices
More
